Appointment sheet
Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma)
Prepared with OnCo (onco.cc/prep/angioimmunoblastic-t-cell-lymphoma/). Orientation, not medical advice; your team knows your case.
My details
Name
Date of appointment
Hospital and clinician
Who is coming with me
What I know, what is unclear, changes to discuss
Saved in this browserWhat I know so far
What is unclear to me
Changes since last time
My questions
11 on the sheetNewly diagnosed
- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example TFH markers: PD1, CXCL13, ICOS, BCL6, CD10, TET2, DNMT3A, RHOA G17V and IDH2 R172 mutations, EBV-positive B immunoblasts, C-reactive protein and beta-2 microglobulin), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
First line
- 5.For my situation (first line), which of the standard options do you recommend and why?
- 6.Am I a candidate for Cyclophosphamide, and what side effects should I expect?
Relapsed
- 7.For my situation (relapsed), which of the standard options do you recommend and why?
- 8.Am I a candidate for Romidepsin, Belinostat, Pralatrexate or related drugs, and what side effects should I expect?
- 9.How do the results of A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype apply to someone like me?
Any stage
- 10.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 11.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
The words I may hear
- R-CHOP (lymphoma chemoimmunotherapy): R-CHOP is the standard first treatment for diffuse large B-cell lymphoma: rituximab (an antibody against CD20) plus four chemotherapy drugs (cyclophosphamide, doxorubicin, vincristine, prednisone), given every three weeks for six cycles with curative intent.
Tests and results to bring
Biomarker results to ask for: TFH markers: PD1, CXCL13, ICOS, BCL6, CD10, TET2, DNMT3A, RHOA G17V and IDH2 R172 mutations, EBV-positive B immunoblasts, C-reactive protein and beta-2 microglobulin (AITL prognostic score).
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- First line: CHOP-based chemotherapy, with etoposide in younger patients, and autologous transplant in first complete remission for fit patients (T-cell Project data). (Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Cyclophosphamide, R-CHOP (lymphoma chemoimmunotherapy))
- Relapsed: Romidepsin, belinostat or pralatrexate; azacitidine with romidepsin; duvelisib in the TFH-phenotype trial TERZO; brentuximab vedotin when CD30-positive. (Romidepsin, Belinostat, Pralatrexate, Azacitidine, Brentuximab vedotin, A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.
Answers and next steps
Saved in this browserWhat I was told
Agreed next steps, dates and who to call